Cancer Immunology, Immunotherapy

, Volume 58, Issue 7, pp 1129–1136 | Cite as

Immunotherapy: from basic research to clinical applications

  • Christina StoeckleEmail author
  • Anne-Kathrin Gleske
Meeting Report


Activation or modulation of host immune responses is emerging as a promising strategy to combat many diseases, including autoimmune disorders and cancer. However, although initial successes have sometimes been encouraging, larger trials have unfortunately often shown only limited efficacy. There is clearly much room for improvement. The development of new therapies and their translation into clinical practice is the aim of the Collaborative Research Centre (Sonderforschungsbereich, SFB) 685, Tübingen, coordinated by Professor Hans-Georg Rammensee. To provide a forum for discussion of new developments, the SFB 685 hosted a symposium on immunotherapy, between 6 and 7 March 2008. The scope of this symposium encompassed basic research topics including NK cell, T cell and antigen-presenting cell (APC) biology as well as clinical applications of therapies developed from such research. Especially, the potentiation or attenuation of specific T cell responses is the common goal of...


Dendritic Cell Sorafenib Sunitinib Cancer Immunotherapy Tumour Eradication 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



We wish to thank Kirsten Lauber for critical proofreading and Andreas Kämper for invaluable technical support.


  1. 1.
    Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F (2007) Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 8(9):942–949PubMedCrossRefGoogle Scholar
  2. 2.
    Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, Sallusto F, Napolitani G (2007) Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 8(6):639–646PubMedCrossRefGoogle Scholar
  3. 3.
    Allan RS, Smith CM, Belz GT, van Lint AL, Wakim LM, Heath WR, Carbone FR (2003) Epidermal viral immunity induced by CD8alpha+ dendritic cells but not by Langerhans cells. Science 301(5641):1925–1928PubMedCrossRefGoogle Scholar
  4. 4.
    Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, Thiel A, Boeld TJ, Hoffmann P, Edinger M, Turbachova I, Hamann A, Olek S, Huehn J (2007) DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 37(9):2378–2389PubMedCrossRefGoogle Scholar
  5. 5.
    Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, Clausen BE (2005) Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 169(4):569–576PubMedCrossRefGoogle Scholar
  6. 6.
    Bettelli E, Korn T, Kuchroo VK (2007) Th17: the third member of the effector T cell trilogy. Curr Opin Immunol 19(6):652–657PubMedCrossRefGoogle Scholar
  7. 7.
    Blank C, Gajewski TF, Mackensen A (2005) Interaction of PD-L1 on tumour cells with PD-1 on tumour-specific T cells as a mechanism of immune evasion: implications for tumour immunotherapy. Cancer Immunol Immunother 54(4):307–314PubMedCrossRefGoogle Scholar
  8. 8.
    Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, Walter B, Majdic O, Gajewski TF, Theobald M, Andreesen R, Mackensen A (2006) Blockade of PD-L1 (B7–H1) augments human tumour-specific T cell responses in vitro. Int J Cancer 119(2):317–327PubMedCrossRefGoogle Scholar
  9. 9.
    Blank C, Mackensen A (2007) Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumour evasion. Cancer Immunol Immunother 56(5):739–745PubMedCrossRefGoogle Scholar
  10. 10.
    Brown GD (2006) Dectin-1: a signalling non-TLR pattern-recognition receptor. Nat Rev Immunol 6(1):33–43PubMedCrossRefGoogle Scholar
  11. 11.
    de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, Ruiter DJ, Figdor CG, Punt CJ, Adema GJ (2005) Immunomonitoring tumour-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23(24):5779–5787PubMedCrossRefGoogle Scholar
  12. 12.
    de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23(11):1407–1413PubMedCrossRefGoogle Scholar
  13. 13.
    Ferch U, zum Buschenfelde CM, Gewies A, Wegener E, Rauser S, Peschel C, Krappmann D, Ruland J (2007) MALT1 directs B cell receptor-induced canonical nuclear factor-[kappa] B signaling selectively to the c-Rel subunit. Nat Immunol 8(9):984–991PubMedCrossRefGoogle Scholar
  14. 14.
    Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M, Castelli C, Mariani L, Parmiani G, Rivoltini L (2007) Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumour vaccine. J Clin Oncol 25(18):2546–2553PubMedCrossRefGoogle Scholar
  15. 15.
    Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, Gottfried E, Schwarz S, Rothe G, Hoves S, Renner K, Timischl B, Mackensen A, Kunz-Schughart L, Andreesen R, Krause SW, Kreutz M (2007) Inhibitory effect of tumour cell-derived lactic acid on human T cells. Blood 109(9):3812–3819PubMedCrossRefGoogle Scholar
  16. 16.
    Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J (2007) Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 5(2):e38PubMedCrossRefGoogle Scholar
  17. 17.
    Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C, Chauffert B, Solary E, Bonnotte B, Martin F (2004) CD4+ CD25+ regulatory T cells suppress tumour immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumours to be curative. Eur J Immunol 34(2):336–344PubMedCrossRefGoogle Scholar
  18. 18.
    Gottfried E, Kunz-Schughart LA, Ebner S, Mueller-Klieser W, Hoves S, Andreesen R, Mackensen A, Kreutz M (2006) Tumour-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 107(5):2013–2021PubMedCrossRefGoogle Scholar
  19. 19.
    Gringhuis SI, den Dunnen J, Litjens M, van het Hof B, van Kooyk Y, Geijtenbeek TBH (2007) C-type lectin DC-SIGN modulates toll-like receptor signaling via Raf–1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 26(5):605–616PubMedCrossRefGoogle Scholar
  20. 20.
    Gross O, Gewies A, Finger K, Schäfer M, Sparwasser T, Peschel C, Förster I, Ruland J (2006) Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature 442(7103):651–656PubMedCrossRefGoogle Scholar
  21. 21.
    Gruber A, Brocker T (2005) MHC class I-positive dendritic cells (DC) control CD8 T Cell homeostasis in vivo: T Cell lymphopenia as a prerequisite for DC-mediated homeostatic proliferation of naive CD8 T Cells. J Immunol 175(1):201–206PubMedGoogle Scholar
  22. 22.
    Guarda G, Hons M, Soriano SF, Huang AY, Polley R, Martin-Fontecha A, Stein JV, Germain RN, Lanzavecchia A, Sallusto F (2007) L-selectin-negative CCR7- effector and memory CD8+ T cells enter reactive lymph nodes and kill dendritic cells. Nat Immunol 8(7):743–752PubMedCrossRefGoogle Scholar
  23. 23.
    Hipp MM, Hilf N, Walter S, Werth D, Brauer KM, Radsak MP, Weinschenk T, Singh-Jasuja H, Brossart P (2008) Sorafenib but not sunitinib affects function of dendritic cells and induction of primary immune responses. Blood 111(2):5610–5620. doi:  10.1128/blood-2007-02-075945 Google Scholar
  24. 24.
    Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, Niemand C, Assenmacher M, Orso E, Andreesen R, Holler E, Edinger M (2006) Isolation of CD4+ CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant 12(3):267–274PubMedCrossRefGoogle Scholar
  25. 25.
    Hoffmann P, Eder R, Boeld TJ, Doser K, Piseshka B, Andreesen R, Edinger M (2006) Only the CD45RA+ subpopulation of CD4+ CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 108(13):4260–4267PubMedCrossRefGoogle Scholar
  26. 26.
    Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M (2004) Large-scale in vitro expansion of polyclonal human CD4+ CD25 high regulatory T cells. Blood 104(3):895–903PubMedCrossRefGoogle Scholar
  27. 27.
    Hofmeister V, Schrama D, Becker JC (2008) Anti-cancer therapies targeting the tumour stroma. Cancer Immunol Immunother 57(1):1–17PubMedCrossRefGoogle Scholar
  28. 28.
    Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann K-K, Schlee M, Endres S, Hartmann G (2006) 5′-Triphosphate RNA Is the Ligand for RIG-I. Science 314(5801):994–997PubMedCrossRefGoogle Scholar
  29. 29.
    Kaplan DH, Jenison MC, Saeland S, Shlomchik WD, Shlomchik MJ (2005) Epidermal langerhans cell-deficient mice develop enhanced contact hypersensitivity. Immunity 23(6):611–620PubMedCrossRefGoogle Scholar
  30. 30.
    Kissenpfennig A, Henri S, Dubois B, Laplace-Builhe C, Perrin P, Romani N, Tripp CH, Douillard P, Leserman L, Kaiserlian D, Saeland S, Davoust J, Malissen B (2005) Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity 22(5):643–654PubMedCrossRefGoogle Scholar
  31. 31.
    Kolanus W (2007) Guanine nucleotide exchange factors of the cytohesin family and their roles in signal transduction. Immunol Rev 218(1):102–113PubMedCrossRefGoogle Scholar
  32. 32.
    Lanzavecchia A, Sallusto F (2002) Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2(12):982–987PubMedCrossRefGoogle Scholar
  33. 33.
    Lennerz V, Fatho M, Gentilini C, Frye RA, Lifke A, Ferel D, Wolfel C, Huber C, Wolfel T (2005) The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci USA 102(44):16013–16018PubMedCrossRefGoogle Scholar
  34. 34.
    Lesterhuis WJ, Aarntzen EH, De Vries IJ, Schuurhuis DH, Figdor CG, Adema GJ, Punt CJ (2008) Dendritic cell vaccines in melanoma: From promise to proof? Crit Rev Oncol Hematol 66(2):118–134PubMedCrossRefGoogle Scholar
  35. 35.
    Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R (2006) Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 24(31):5060–5069PubMedCrossRefGoogle Scholar
  36. 36.
    Neijssen J, Herberts C, Drijfhout JW, Reits E, Janssen L, Neefjes J (2005) Cross-presentation by intercellular peptide transfer through gap junctions. Nature 434(7029):83–88PubMedCrossRefGoogle Scholar
  37. 37.
    Patel PH, Chaganti RS, Motzer RJ (2006) Targeted therapy for metastatic renal cell carcinoma. Br J Cancer 94(5):614–619PubMedGoogle Scholar
  38. 38.
    Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J Exp Med 203(5):1259–1271PubMedCrossRefGoogle Scholar
  39. 39.
    Rivoltini L, Canese P, Huber V, Iero M, Pilla L, Valenti R, Fais S, Lozupone F, Casati C, Castelli C, Parmiani G (2005) Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5(4):463–476PubMedCrossRefGoogle Scholar
  40. 40.
    Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708–712PubMedCrossRefGoogle Scholar
  41. 41.
    Sentman CL, Barber MA, Barber A, T Zhang (2006) NK cell receptors as tools in cancer immunotherapy. In: George F. Vande Woude, George Klein (eds) Advances in cancer research, vol 95. Academic press, pp 249–292Google Scholar
  42. 42.
    Stagg J, Smyth MJ (2007) NK cell-based cancer immunotherapy. Drug News Perspect 20(3):155–163PubMedCrossRefGoogle Scholar
  43. 43.
    Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 19(3):281–286PubMedCrossRefGoogle Scholar
  44. 44.
    Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F (2008) Tumour immunotherapy by epicutaneous immunization requires langerhans cells. J Immunol 180(3):1991–1998PubMedGoogle Scholar
  45. 45.
    Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, Bursch L, Ronchese F, Romani N (2006) Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci USA 103(20):7783–7788PubMedCrossRefGoogle Scholar
  46. 46.
    Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, Figdor CG (2005) Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 106(4):1278–1285PubMedCrossRefGoogle Scholar
  47. 47.
    Tacken PJ, de Vries IJ, Torensma R, Figdor CG (2007) Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 7(10):790–802PubMedCrossRefGoogle Scholar
  48. 48.
    Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, Blute ML, Sebo TJ, Cheville JC, Kwon ED (2006) Tumour B7–H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 66(7):3381–3385PubMedCrossRefGoogle Scholar
  49. 49.
    van Vliet SJ, den Dunnen J, Gringhuis SI, Geijtenbeek TB, van Kooyk Y (2007) Innate signaling and regulation of Dendritic cell immunity. Curr Opin Immunol 19(4):435–440PubMedCrossRefGoogle Scholar
  50. 50.
    Walzer T, Blery M, Chaix J, Fuseri N, Chasson L, Robbins SH, Jaeger S, Andre P, Gauthier L, Daniel L, Chemin K, Morel Y, Dalod M, Imbert J, Pierres M, Moretta A, Romagne F, Vivier E (2007) Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc Natl Acad Sci USA 104(9):3384–3389PubMedCrossRefGoogle Scholar
  51. 51.
    Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, Jacques Y, Baratin M, Tomasello E, Vivier E (2007) Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 8(12):1337–1344PubMedCrossRefGoogle Scholar
  52. 52.
    Walzer T, Jaeger S, Chaix J, Vivier E (2007) Natural killer cells: from CD3-NKp46+ to post-genomics meta-analyses. Curr Opin Immunol 19(3):365–372PubMedCrossRefGoogle Scholar
  53. 53.
    Welte S, Kuttruff S, Waldhauer I, Steinle A (2006) Mutual activation of natural killer cells and monocytes mediated by NKp80-AICL interaction. Nat Immunol 7(12):1334–1342PubMedCrossRefGoogle Scholar
  54. 54.
    Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L, Brossart P (2006) Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res 66(11):5910–5918PubMedCrossRefGoogle Scholar
  55. 55.
    Yu YA, Shabahang S, Timiryasova TM, Zhang Q, Beltz R, Gentschev I, Goebel W, Szalay AA (2004) Visualization of tumours and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. Nat Biotech 22(3):313–320CrossRefGoogle Scholar
  56. 56.
    Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, Marincola FM, Szalay AA (2007) Eradication of solid human breast tumours in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 67(20):10038–10046PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  1. 1.Department of General Neurology, Hertie Institute for Clinical Brain ResearchUniversity of TübingenTübingenGermany
  2. 2.Cellular and Molecular Microbiology Section, Medical Microbiology and Hygiene DepartmentUniversity of TübingenTübingenGermany

Personalised recommendations